IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
0.9600
-0.0750 (-7.25%)
Aug 3, 2026, 3:16 PM EDT - Market open

IN8bio Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-18.98-19.44-30.44-30.01-28.52-14.65
Net Income
-18.98-19.44-30.44-30.01-28.52-14.65
Earnings Per Share
-2.61-4.44-17.05-30.00-40.80-44.10
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
21.9427.0911.1221.2818.1837.02
Total Debt
2.352.785.034.895.872.41
Net Cash (Debt)
19.5924.316.0916.3912.3134.61
Net Cash Growth
157.18%299.18%-62.84%33.16%-64.44%94.23%
Net Cash Per Share
2.225.563.4116.4617.61104.15

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-14.54-12.71-24.15-23.34-24.12-13.51
Capital Expenditures
-0.01--0.19-0.6-3.71-0.31
Free Cash Flow
-14.55-12.71-24.34-23.94-27.83-13.82
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.